FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 477 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 6 of the biggest good news cancer stories of 2021 December 15, 2021 Patient Guide in Prostate Cancer Now Available Also in German December 18, 2025 Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs June 25, 2020 Load more HOT NEWS Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection... Study Finds Possible New Treatment for Metastatic Breast Cancer That Has... Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2...
